Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

24.68 +0.26 (+1.06%)
Streaming Delayed Price Updated: 9:33 AM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,178
Open 24.84
Bid (Size) 24.50 (3)
Ask (Size) 24.86 (2)
Prev. Close 24.42
Today's Range 24.61 - 24.84
52wk Range 13.57 - 42.52
Shares Outstanding 55,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Why Arvinas (ARVN) Shares Are Seeing Blue Skies
Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement. 
Via Benzinga

Performance

YTD
-26.02%
-26.02%
1 Month
+63.66%
+63.66%
3 Month
-6.80%
-6.80%
6 Month
-18.63%
-18.63%
1 Year
-36.69%
-36.69%

More News

Read More
Arvinas Announces Oversubscribed $350 Million Private Placement
From Arvinas Inc.
Via GlobeNewswire
Analyst Ratings for Arvinas
Via Benzinga
Analyst Expectations for Arvinas's Future
Via Benzinga
Where Arvinas Stands With Analysts
Via Benzinga
7 Analysts Have This to Say About Arvinas
Via Benzinga
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know
Via Benzinga
What 8 Analyst Ratings Have To Say About Arvinas
Via Benzinga
6 Analysts Have This to Say About Arvinas
Via Benzinga
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
From Arvinas Inc.
Via GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
Via Benzinga
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.